Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23063Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Antoniou, K. | en |
| dc.contributor.author | Malamas, M. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.date.accessioned | 2015-11-24T19:30:17Z | - |
| dc.date.available | 2015-11-24T19:30:17Z | - |
| dc.identifier.issn | 1744-7666 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23063 | - |
| dc.rights | Default Licence | - |
| dc.subject | Animals | en |
| dc.subject | Cyclooxygenase 2/metabolism | en |
| dc.subject | Cyclooxygenase 2 Inhibitors/adverse effects/*pharmacology/therapeutic use | en |
| dc.subject | Humans | en |
| dc.subject | Membrane Proteins/*antagonists & inhibitors/metabolism | en |
| dc.subject | Pyrazoles/adverse effects/*pharmacology/therapeutic use | en |
| dc.subject | Sulfonamides/adverse effects/*pharmacology/therapeutic use | en |
| dc.title | Clinical pharmacology of celecoxib, a COX-2 selective inhibitor | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1517/14656566.8.11.1719 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17685888 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1517/14656566.8.11.1719 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2007 | - |
| heal.abstract | NSAIDs are extensively used worldwide; nonetheless, they are associated with adverse gastrointestinal (GI) effects. COX-2 inhibitors (coxibs) have been developed to reduce pain and inflammation without associated GI and bleeding risks. Celecoxib was the first COX-2 inhibitor introduced on the market, and it still remains so, whereas rofecoxib and valdecoxib were withdrawn due to excess cardiovascular (CV) risk. There is consequently a concern that CV toxicity reflects a class effect of all COX-2 inhibitors. Celecoxib possesses anti-inflammatory and analgesic properties, and the evidence for CV risk is rather small and comparable to that of other traditional NSAIDs in short-term treatments (of < 4 weeks). It could be suggested that the use of low doses of celecoxib (100 mg b.i.d.) in short-treatment, especially in patients with previous experience of GI events and the recommendation of avoiding use of celecoxib in patients with CV history or risk, contribute in the decision-making process of prescribing COX-2 or NSAIDs. | en |
| heal.journalName | Expert Opin Pharmacother | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
